Literature DB >> 9303897

[Goals and practical implementation of lipid therapy in coronary heart disease].

F U Beil1, E Windler.   

Abstract

In all patients with coronary heart disease a fasting lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides) should be obtained. Hyperlipidemias can then be classified as hypercholesterolemia (LDL cholesterol elevated), mixed hyperlipidemia (LDL cholesterol elevated, triglycerides elevated) and hypertriglyceridemia (triglycerides elevated). Primary goal of lipid intervention is a LDL cholesterol < 100 mg/dl, secondary goals are HDL cholesterol > 35 mg/dl and triglycerides < 200 mg/dl. These goals can be reached by dietary intervention alone (reduction in fat and modification of fat intake) or in combination with lipid lowering drugs. Monotherapy with HMG-CoA reductase inhibitors or combined therapy with bile acid sequestrants will allow a reduction in LDL cholesterol by more than 50%; in predominant hypertriglyceridemia fibrates or nicotinic acid will lower triglycerides and elevate HDL cholesterol.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9303897     DOI: 10.1007/BF03044350

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  36 in total

1.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

Authors: 
Journal:  JAMA       Date:  1993-06-16       Impact factor: 56.272

Review 2.  Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension.

Authors:  K Pyörälä; G De Backer; I Graham; P Poole-Wilson; D Wood
Journal:  Atherosclerosis       Date:  1994-10       Impact factor: 5.162

3.  Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin.

Authors:  D R Illingworth; D W Erkelens; U Keller; G R Thompson; M J Tikkanen
Journal:  Lancet       Date:  1994-06-18       Impact factor: 79.321

4.  Dietary fat induces changes in factor VII coagulant activity through effects on plasma free stearic acid concentration.

Authors:  K A Mitropoulos; G J Miller; J C Martin; B E Reeves; J Cooper
Journal:  Arterioscler Thromb       Date:  1994-02

5.  Glucose tolerance and insulin response to glucose in nondiabetic young male survivors of myocardial infarction.

Authors:  A Hamsten; S Eféndic; G Walldius; A Szamosi; U de Faire
Journal:  Am Heart J       Date:  1987-04       Impact factor: 4.749

6.  Low-density lipoprotein subclass patterns and risk of myocardial infarction.

Authors:  M A Austin; J L Breslow; C H Hennekens; J E Buring; W C Willett; R M Krauss
Journal:  JAMA       Date:  1988-10-07       Impact factor: 56.272

7.  Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.

Authors:  R G Bakker-Arkema; M H Davidson; R J Goldstein; J Davignon; J L Isaacsohn; S R Weiss; L M Keilson; W V Brown; V T Miller; L J Shurzinske; D M Black
Journal:  JAMA       Date:  1996-01-10       Impact factor: 56.272

8.  High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia.

Authors:  O Eliav; D Schurr; P Pfister; Y Friedlander; E Leitersdorf
Journal:  Am J Cardiol       Date:  1995-07-13       Impact factor: 2.778

9.  Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial.

Authors:  D Ornish; S E Brown; L W Scherwitz; J H Billings; W T Armstrong; T A Ports; S M McLanahan; R L Kirkeeide; R J Brand; K L Gould
Journal:  Lancet       Date:  1990-07-21       Impact factor: 79.321

10.  Efficacy of a National Cholesterol Education Program Step 2 diet in normolipidemic and hypercholesterolemic middle-aged and elderly men and women.

Authors:  E J Schaefer; A H Lichtenstein; S Lamon-Fava; J H Contois; Z Li; H Rasmussen; J R McNamara; J M Ordovas
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-08       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.